Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

執行長

Dr. Ellen K. Donnelly Ph.D.

員工

國家

上市

0 Comments

分享你的想法

FAQ

ABLIVA AB 今天的股價是多少？▼

NEVPF 目前價格為 $0.03 USD，過去 24 小時上漲了 +0%。在圖表上更密切關注 ABLIVA AB 股價表現。

ABLIVA AB 的股票代號是什麼？▼

根據交易所不同，股票代號可能會有所差異。例如，在交易所，ABLIVA AB 的股票以代號 NEVPF 進行交易。

ABLIVA AB 去年的營收是多少？▼

ABLIVA AB 去年的營收為 0USD。

ABLIVA AB 去年的淨利是多少？▼

NEVPF 去年的淨收益為 -14.21MUSD。

ABLIVA AB 有多少名員工？▼

截至 April 01, 2026，公司共有 6 名員工。

ABLIVA AB 位於哪個產業？▼

ABLIVA AB從事於Health Care產業。

ABLIVA AB 何時完成拆股？▼

ABLIVA AB 最近沒有進行任何拆股。

ABLIVA AB 的總部在哪裡？▼

ABLIVA AB 的總部位於 SE 的 Lund。